Tags Archive Navigation
-
介质释放,介质释放 Novartis NATALEE study shows Kisqali®reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease -
介质释放,介质释放 Novartis Scemblix®Phase III data first to show superior efficicacy with a favorable safety and tolerability简介vs.standard-of-care TKIs in adults with newly diagnosed CML -
介质释放,介质释放 Novartis Phase III data confirm sustained efficy and long-term safety of oral remibrutinib in chronic spontaneous urticaria -
介质释放,介质释放 Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy(IgAN)portfolio -
介质释放,介质释放 Novartis presents latest Phase III Fabhalta ® (iptacopan)data inC3glomerulopathy(C3G)showing clinically meaningful and statistically significant35.1%proteinuria reduction vs.placebo -
介质释放,介质释放 Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR68 per share in cash -
介质释放,介质释放 地下Venture announce positive efficicacy and safety data for annovel treatment for babies<5kg with malaria -
介质释放,介质释放 Novartis delivers double-digit sales growth and core margin expansion in Q1;FY2024 guidance raised -
介质释放,介质释放 Novartis,au premier trimestre:croissanceàdeux chiffres du chiffre d′affaires et expansion de la marge core; hausse des prévisions pour 2024 -
介质释放,介质释放 Novartis erzielt im ersten Quartal einzweistelliges Umsatzwachstum und steigert die Kerngewinnmarge;Prognose für das Geschäftsjahr2024erhöht -
介质释放,介质释放 新Novartis Fabhalta®(iptacopan)data show clinically meaningful and statistically significant proteinuria reduction of 38.3%versus placebo for patients with IgA nephropathy(IgAN) -
介质释放,介质释放 新Novartis data show early addition of twice-yearly*Leqvio®(inclisiran)following maximally tolerated statin therapy significantly reduces LDL-cin ASCVD patients in real-world setting